Novel anti-fungals

With the decreasing efficacy of many current anti-fungal therapies and the growing problem of fungal infections in the community, researchers are searching for new families of potential therapeutics.

Randall C Willis
BOTHELL, Wash.—With the decreasing efficacy of many current anti-fungal therapies and the growing problem of fungal infections in the community, researchers are searching for new families of potential therapeutics. At the recent American Society of Microbiology conference in Toronto, scientists from Helix Biomedix described the characterization of novel lipohexapeptides as topical therapeutics.
 
Using a combination of rational design and antimicrobial screening, the researchers generated antimicrobial hexapeptides that they modified through acylation or by including D-form, unusual, or non-natural amino acids. They tested the peptide library against organisms involved in athlete's foot, ringworm, nail fungus, and vaginal candidiasis, both in culture (liquid or plate) and in a guinea pig model of dermatophytosis.
 
They found that lipohexapeptides had potent activity against C. albicans as well as fungicidal activity against Trichophyton spp., while a non-acylated hexapeptide candidate appeared to be fungistatic. Similarly, two of the hexapeptide candidates significantly inhibited fungal growth in the animal model without signs of toxicity, either clinically or histopathologically.

Randall C Willis

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

February 2023 Front Cover

Latest Issue  

• Volume 19 • Issue 2 • February 2023

February 2023

February 2023 Issue